Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $170000.0.

  • Spyre Therapeutics' Other Accumulated Expenses fell 6768.06% to $170000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $170000.0, marking a year-over-year decrease of 6768.06%. This contributed to the annual value of $501000.0 for FY2024, which is 266.39% up from last year.
  • Spyre Therapeutics' Other Accumulated Expenses amounted to $170000.0 in Q3 2025, which was down 6768.06% from $242000.0 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Other Accumulated Expenses registered a high of $1.1 million during Q2 2021, and its lowest value of $170000.0 during Q3 2025.
  • Over the past 5 years, Spyre Therapeutics' median Other Accumulated Expenses value was $386000.0 (recorded in 2023), while the average stood at $489352.9.
  • As far as peak fluctuations go, Spyre Therapeutics' Other Accumulated Expenses skyrocketed by 9782.02% in 2022, and later plummeted by 6768.06% in 2025.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Other Accumulated Expenses stood at $783000.0 in 2021, then crashed by 57.85% to $330000.0 in 2022, then skyrocketed by 47.88% to $488000.0 in 2023, then rose by 2.66% to $501000.0 in 2024, then tumbled by 66.07% to $170000.0 in 2025.
  • Its Other Accumulated Expenses was $170000.0 in Q3 2025, compared to $242000.0 in Q2 2025 and $371000.0 in Q1 2025.